Prab: CSV import

2025-03-17T11:59:31Z

CSV import

← Older revision		Revision as of 11:59, 17 March 2025
Line 43:		Line 43:
	{{Medicine-stub}}		{{Medicine-stub}}
	{{No image}}		{{No image}}
			__NOINDEX__

Prab: CSV import

2025-02-10T18:09:05Z

CSV import

← Older revision		Revision as of 18:09, 10 February 2025
Line 42:		Line 42:

	{{Medicine-stub}}		{{Medicine-stub}}
			{{No image}}

Prab: CSV import

2024-03-19T09:57:35Z

CSV import

New page

'''Glycogen storage disease type I''' (GSD I), also known as '''Gierke disease''', is a group of inherited [[metabolic disorders]] characterized by the impairment of glycogen breakdown, leading to the accumulation of glycogen in the [[liver]] and [[kidneys]]. It is named after the German physician Edgar Gierke, who first described the disease in 1929. GSD I is the most common type of glycogen storage disease, and it primarily affects the liver, resulting in a wide range of symptoms including hypoglycemia, lactic acidosis, hyperuricemia, and hyperlipidemia.

==Classification==
GSD I is divided into two main subtypes based on the specific enzyme deficiency:
* '''GSD Ia''' is caused by a deficiency in the enzyme glucose-6-phosphatase-α (G6Pase-α), which is crucial for glucose production from glycogenolysis and gluconeogenesis.
* '''GSD Ib''' is due to a deficiency in the glucose-6-phosphate transporter (G6PT), which transports glucose-6-phosphate into the endoplasmic reticulum where G6Pase-α is located.

==Symptoms and Signs==
Individuals with GSD I typically present in infancy with symptoms related to hypoglycemia, such as irritability, tremors, and seizures. Other common symptoms include:
* Enlarged liver (hepatomegaly)
* Poor growth
* Lactic acidosis
* Hyperuricemia (excess of uric acid in the blood)
* Hyperlipidemia (high levels of lipids in the blood)
* Kidney disease in later stages

==Diagnosis==
Diagnosis of GSD I involves a combination of clinical evaluation, laboratory testing, and genetic testing. Laboratory tests may reveal low blood sugar, high levels of lactate, uric acid, and lipids. Genetic testing can confirm the specific subtype of GSD I by identifying mutations in the [[G6PC]] gene for GSD Ia or the [[SLC37A4]] gene for GSD Ib.

==Treatment==
Management of GSD I focuses on maintaining normal blood glucose levels and preventing the complications associated with the disease. Treatment strategies include:
* Frequent meals high in complex carbohydrates
* Cornstarch therapy to provide a slow-release form of glucose
* Medications to treat hyperuricemia and hyperlipidemia
* Liver transplantation in severe cases

==Prognosis==
With appropriate management, individuals with GSD I can lead relatively normal lives, although they may continue to experience some complications related to the disease. Early diagnosis and treatment are crucial to prevent severe complications.

==Epidemiology==
GSD I is a rare disorder, with an estimated incidence of 1 in 100,000 to 1 in 140,000 live births worldwide. Both males and females are equally affected.

==See Also==
* [[Glycogen storage disease]]
* [[Metabolic disorder]]
* [[Hypoglycemia]]
* [[Liver transplantation]]

[[Category:Inherited disorders]]
[[Category:Metabolic disorders]]
[[Category:Glycogen storage diseases]]

{{Medicine-stub}}

Gierke - Revision history

Prab: CSV import

Prab: CSV import

Prab: CSV import